-

Reinsurance Group of America Reinsures 200 Billion JPY of Statutory Reserves From Dai-ichi Life Insurance Company

TOKYO--(BUSINESS WIRE)--Reinsurance Group of America, Incorporated (NYSE: RGA) a leading global life and health reinsurer, today announced that it reached an agreement with The Dai-ichi Life Insurance Company, Limited to reinsure 200 billion JPY of statutory reserves through coinsurance. The effective date of the transaction was March 31, 2021.

“Following on a transaction we completed with Dai-ichi last year, we are excited to continue to work with them to optimize capital and grow our strong partnership,” said Larry Carson, Executive Vice President, Global Financial Solutions, RGA. “We have a steady pipeline of opportunities available in Japan and across Asia, and we expect continued growth of our asset intensive business in the Asia market.”

Dai-ichi were appreciative of the partnership with RGA, “Our longstanding relationship with RGA made them an ideal partner in this transaction. We were able to tailor a solution to meet our specific needs, and we appreciate RGA’s support as we work to reinforce our balance sheet.”

Additional terms of the transaction are not being disclosed at this time.

About RGA

Reinsurance Group of America, Incorporated (RGA), a Fortune 500 company, is among the leading global providers of life reinsurance and financial solutions, with approximately $3.4 trillion of life reinsurance in force and assets of $84.8 billion as of March 31, 2021. Founded in 1973, RGA today is recognized for its deep technical expertise in risk and capital management, innovative solutions, and commitment to serving its clients. With headquarters in St. Louis, Missouri, and operations around the world, RGA delivers expert solutions in individual life reinsurance, individual living benefits reinsurance, group reinsurance, health reinsurance, facultative underwriting, product development, and financial solutions. To learn more about RGA and its businesses, visit the company’s website at www.rgare.com.

Contacts

Lynn Phillips
Vice President, Corporate Communications
636-736-2351
lphillips@rgare.com

Lizzie Curry
Director, Public Relations
636-736-8521
lizzie.curry@rgare.com

Jeff Hopson
Senior Vice President, Investor Relations
636-736-2068
jhopson@rgare.com

Reinsurance Group of America, Incorporated

NYSE:RGA

Release Versions

Contacts

Lynn Phillips
Vice President, Corporate Communications
636-736-2351
lphillips@rgare.com

Lizzie Curry
Director, Public Relations
636-736-8521
lizzie.curry@rgare.com

Jeff Hopson
Senior Vice President, Investor Relations
636-736-2068
jhopson@rgare.com

More News From Reinsurance Group of America, Incorporated

Reinsurance Group of America Named to Fortune’s ‘World’s Most Admired Companies’ List

ST. LOUIS--(BUSINESS WIRE)--Reinsurance Group of America, Incorporated (NYSE: RGA), a leading global life and health insurer, has been named to Fortune’s World’s Most Admired Companies list, a testament to RGA’s dedication to excellence and unwavering focus on delivering value to clients while upholding the highest standards of business operations and corporate responsibility. “We’re truly honored to be recognized by Fortune once again. It reflects the passion and commitment our employees bring...

Reinsurance Group of America Names Ryan Krueger Senior Vice President, Investor Relations

ST. LOUIS--(BUSINESS WIRE)--Reinsurance Group of America, Incorporated (NYSE: RGA), a leading global life and health reinsurer, announced today that Ryan Krueger will join the company as Senior Vice President, Investor Relations, effective January 5, 2026. In this role, he will lead RGA’s engagement with the investor community, partnering closely with the company’s executive leadership team to articulate RGA’s strategic evolution and performance. Mr. Krueger will report to Executive Vice Presid...

New Research from RGA: GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20 Years

ST. LOUIS--(BUSINESS WIRE)--Reinsurance Group of America, Incorporated (NYSE: RGA), a leading global life and health reinsurer, published new in-depth research quantifying the mortality and morbidity impacts of incretin-based therapies, including GLP-1s, approved as anti-obesity medications (AOMs) and diabetes treatments. The study examined data from four markets (US, UK, Canada, and Hong Kong) to assess how widespread adoption of AOMs could affect population health outcomes over the next two d...
Back to Newsroom